Despite having 8 adalimumab biosimilars on the market now, patients may only see 1 or 2 available through their insurance, explained Laura Wingate, executive vice president, Education, Support, & Advocacy, Crohn's & Colitis Foundation.
Having 7 adalimumab biosimilars come to the market at the same time, and a total of 8 launch over the first half of 2023, is a unique experience for biosimilars in the United States. This can be confusing for patients, especially if they only see 1 or 2 available through their insurance, explained Laura Wingate, executive vice president, Education, Support, & Advocacy, Crohn's & Colitis Foundation.
Transcript
What are the challenges of having so many biosimilars available for the same originator product in such a short amount of time?
For the Foundation, we've been making patients aware of the approvals—once they got approved, we've been educating on them. But we've been doing consistent education since and reminding people that all of these launches have taken place, and they are all biosimilars to Humira. It is a little confusing that all of these biosimilars are coming out at once. But again, I lean into the importance of patient education, awareness building, helping patients understand that all of these products are available, but they may be only seeing 1 or 2 that's available from their insurance companies.
The insurers have a role to play here in helping patients understand what's available in terms of the biosimilars to Humira, and Remicade [infliximab] for that matter, but also giving them the resources to understand the terminology, the effectiveness, and all the information that they need to engage in an appropriate decision on what treatment's right for them.
There have been infliximab biosimilars on the market for a few years. Do you think that experience will help smooth the way for adoption of adalimumab biosimilars?
We're optimistic that it will. With experience, with knowledge that there haven't been patients who experienced immunogenicity and didn't do well on these drugs, that's going to help our health care professionals be more comfortable in prescribing the adalimumab biosimilars. But we also are going to leverage the patients who've been on Remicade biosimilars for the last few years to tell their stories and help other patients and caregivers understand that biosimilars are good. They're safe, they're effective, and should be part of every patient's consideration when they're talking to their doctor about a biologic or biosimilar.
Diagnostic Oversights Limit Luspatercept Benefits in MDS
May 8th 2024Investigators of a retrospective study encourage colleagues to utilize molecular testing for patients with an established diagnosis of lower-risk myelodysplastic syndromes (MDS), to be sure they don’t miss out on treatments, like luspatercept, for which they qualify.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
AUA Session Highlights the General Urologist’s Role in Gender-Affirming Care
May 7th 2024During her session, Polina Reyblat, MD, Kaiser Permanente Los Angeles Medical Center, highlighted best practices urologists should incorporate to make transgender and gender-diverse patients comfortable during physical exams and avoid retraumatization.
Read More